These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 23302304)

  • 81. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
    Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
    Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan.
    Liu HP; Isaac Wu HD; Chang JW; Wu YC; Yang HY; Chen YT; Hsieh WY; Chen YT; Chen YR; Huang SF
    J Thorac Oncol; 2010 Aug; 5(8):1175-84. PubMed ID: 20559151
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
    Glynn C; Zakowski MF; Ginsberg MS
    J Thorac Oncol; 2010 Mar; 5(3):344-8. PubMed ID: 20087229
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
    Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
    [TBL] [Abstract][Full Text] [Related]  

  • 86. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
    Jackman DM; Miller VA; Cioffredi LA; Yeap BY; Jänne PA; Riely GJ; Ruiz MG; Giaccone G; Sequist LV; Johnson BE
    Clin Cancer Res; 2009 Aug; 15(16):5267-73. PubMed ID: 19671843
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
    Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.
    Ren S; Kuang P; Zheng L; Su C; Li J; Li B; Chen X; Wang Y; KimCurran V; Liu L; Hu Q; Zhang J; Tang L; Zhou C
    Cell Biochem Biophys; 2012 Nov; 64(2):155-60. PubMed ID: 22707299
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Molecular analysis of genetic mutations in non-small cell lung cancer in Morocco.
    Morjani O; Benkirane N; Errihani H; Elfahime EM; Lakhiari H
    Pan Afr Med J; 2024; 47():116. PubMed ID: 38828424
    [TBL] [Abstract][Full Text] [Related]  

  • 91. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
    Rotella V; Fornaro L; Vasile E; Tibaldi C; Boldrini L; Chella A; D'Incecco A; Cirigliano G; Chioni A; Lupi C; Sensi E; Ginocchi L; Giovannelli S; Pennucci MC; Fontanini G; Baldini E
    J Exp Clin Cancer Res; 2014 Oct; 33(1):77. PubMed ID: 25300933
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
    Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
    Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
    [TBL] [Abstract][Full Text] [Related]  

  • 94. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
    Mao C; Qiu LX; Liao RY; Du FB; Ding H; Yang WC; Li J; Chen Q
    Lung Cancer; 2010 Sep; 69(3):272-8. PubMed ID: 20022659
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.
    Folch E; Yamaguchi N; VanderLaan PA; Kocher ON; Boucher DH; Goldstein MA; Huberman MS; Kent MS; Gangadharan SP; Costa DB; Majid A
    J Thorac Oncol; 2013 Nov; 8(11):1438-1444. PubMed ID: 24128714
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Detection of EGFR and K-ras mutations in non-small cell lung cancer using cytological specimens].
    Lu SS; Xu X; Guo HQ; Cao J; Pan QJ; Wang MR
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):585-9. PubMed ID: 24314215
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.
    Dacic S; Shuai Y; Yousem S; Ohori P; Nikiforova M
    Mod Pathol; 2010 Feb; 23(2):159-68. PubMed ID: 19855375
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.
    Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
    J Thorac Oncol; 2011 Jan; 6(1):15-20. PubMed ID: 21150464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.